LSE - Delayed Quote GBP

Mercer Short Dur Glbl Bd1 A11 0.2450GBPH (0P0001HP5B.L)

115.89

-0.22

(-0.19%)

As of May 12 at 9:00:00 PM GMT+1. Market Open.

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skele

GlobeNewswire 18 hours ago

ASND
Ares Management Stock Scores Relative Strength Rating Upgrade

Ares Management shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily 19 hours ago

ARES

AAMI

SII
3 Top-Ranked Mutual Funds for Your Retirement

Take a look at these three top-ranked, best-performing and well-managed mutual funds if you're looking to maximize your retirement portfolio returns.

Zacks yesterday

AMECX

AMEFX

CIMAX
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE & ESE 2025, the joint congress of the European Society fo

GlobeNewswire yesterday

ASND
Sprott Physical Uranium Trust Raises US$25.55 Million Through Non-Brokered Private Placement

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott”) on behalf of the Sprott Physical Uranium Trust (TSX: U.UN) (TSX: U.U) (“SPUT” or the “Trust”) today announced that SPUT has completed a US$25.55 million non-brokered private placement of trust units. The proceeds are expected to be used to cover general operating expenses of the Trust for the next year. “We launched SPUT with the objective of providing investors with the most liquid and efficient way to invest in ph

GlobeNewswire 2 days ago

SII

SRUUF
Uncovering 3 Promising Canadian Small Caps Backed By Solid Fundamentals

With Canada's election now concluded, a significant source of uncertainty has been lifted, allowing the government to focus on key issues such as trade and economic growth. As policymakers consider fiscal stimulus and potential interest rate cuts to support the economy, investors may find opportunities in Canadian small-cap stocks that are backed by solid fundamentals.

Simply Wall St. 6 days ago

SII

TNEYF

HLNFF
Sprott First Quarter 2025 Earnings: EPS: US$0.46 (vs US$0.46 in 1Q 2024)

Sprott ( TSE:SII ) First Quarter 2025 Results Key Financial Results Revenue: US$43.4m (up 4.4% from 1Q 2024). Net...

Simply Wall St. 6 days ago

SII
Sprott Inc. Announces Results of its Annual Meeting of Shareholders

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (“Sprott”) (NYSE/TSX: SII) announced today the results of its Annual Meeting of shareholders held on May 7, 2025 (the “Meeting”). Sprott is pleased to announce that all resolutions put forward in the Management Information Circular dated March 18, 2025 (the “Circular”) to its shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Sprott’s seven (7) director nominees were elected: No

GlobeNewswire 6 days ago

SII
Sprott Announces First Quarter 2025 Results

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2025. Management commentary "Sprott’s Assets Under Management (“AUM”) ended the first quarter of 2025 at $35.1 billion, up 11% from $31.5 billion as at December 31, 2024," said Whitney George, Chief Executive Officer of Sprott. "Our AUM growth during the quarter was driven by surging gold prices and strong inflows to our physical

GlobeNewswire 7 days ago

SII
Sprott Inc. Declares First Quarter 2025 Dividend

TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (“Sprott” or the “Company”) (NYSE/TSX: SII) announced today that its Board of Directors has declared a first quarter 2025 dividend of US$0.30 per common share, payable on June 4, 2025 to shareholders of record at the close of business on May 20, 2025. Registered shareholders who are residents of Canada as reflected in the Company’s shareholders register, as well as beneficial holders (i.e., shareholders who hold their common shares through a

GlobeNewswire 7 days ago

SII
UK Penny Stocks Worth Watching In May 2025

The UK market has been experiencing fluctuations, with the FTSE 100 index closing lower due to weak trade data from China, impacting companies tied to Chinese economic performance. Despite these broader market challenges, penny stocks—often representing smaller or newer companies—remain an intriguing area for investors seeking growth opportunities at lower price points. By focusing on those with strong financial foundations and potential for long-term growth, investors can discover hidden...

Simply Wall St. 9 days ago

BKS.L

HSWLF

ALLIF
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4

GlobeNewswire 9 days ago

ASND
Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think

It's been a good week for Ascendis Pharma A/S ( NASDAQ:ASND ) shareholders, because the company has just released its...

Simply Wall St. 10 days ago

ASND
Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2025 Results Key Financial Results Revenue: €101.0m (up 5.3% from 1Q...

Simply Wall St. 11 days ago

ASND
3 Mutual Funds to Buy on Steady Growth in Semiconductor Sales

Funds like KTCAX, FSPTX and ROGSX are likely to benefit form the jump in semiconductors sales.

Zacks 11 days ago

ROGSX

FSPTX

KTCAX
Sprott Announces Date for 2025 First Quarter Results Webcast

TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE:SII) (TSX:SII) (“Sprott”) announced today that it plans to release its 2025 first quarter results at 7:00 a.m. on May 7, 2025. Sprott will host an earnings webcast that morning at 10:00 a.m. to discuss the results. Sprott CEO, Whitney George, together with Sprott CFO, Kevin Hibbert and Sprott Asset Management CEO, John Ciampaglia, will host the webcast, which can be accessed as outlined below. Webcast DetailsDate: May 7, 2025Time: 10:00

GlobeNewswire 12 days ago

SII
Ascendis Pharma Reports First Quarter 2025 Financial Results

- Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025 - Conference call today at 4:30 pm ET COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “The strong glob

GlobeNewswire 12 days ago

ASND
EML Payments (ASX:EML) shareholders have endured a 68% loss from investing in the stock five years ago

While it may not be enough for some shareholders, we think it is good to see the EML Payments Limited ( ASX:EML ) share...

Simply Wall St. 13 days ago

EMCHF
Investing in Sprott (TSE:SII) five years ago would have delivered you a 147% gain

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Simply Wall St. 15 days ago

SII
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results. Those who would like to participate may access the live webcast here, or

GlobeNewswire 19 days ago

ASND

Return	0P0001HP5B.L	Category
YTD	+1.92%	--
1-Year	+6.78%	--
3-Year	+4.56%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mercer Short Dur Glbl Bd1 A11 0.2450GBPH (0P0001HP5B.L)

Related Mutual Fund News

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

Ares Management Stock Scores Relative Strength Rating Upgrade

3 Top-Ranked Mutual Funds for Your Retirement

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Sprott Physical Uranium Trust Raises US$25.55 Million Through Non-Brokered Private Placement

Uncovering 3 Promising Canadian Small Caps Backed By Solid Fundamentals

Sprott First Quarter 2025 Earnings: EPS: US$0.46 (vs US$0.46 in 1Q 2024)

Sprott Inc. Announces Results of its Annual Meeting of Shareholders

Sprott Announces First Quarter 2025 Results

Sprott Inc. Declares First Quarter 2025 Dividend

UK Penny Stocks Worth Watching In May 2025

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

3 Mutual Funds to Buy on Steady Growth in Semiconductor Sales

Sprott Announces Date for 2025 First Quarter Results Webcast

Ascendis Pharma Reports First Quarter 2025 Financial Results

EML Payments (ASX:EML) shareholders have endured a 68% loss from investing in the stock five years ago

Investing in Sprott (TSE:SII) five years ago would have delivered you a 147% gain

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Performance Overview